Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CATALYST BIOSCIENCES, INC.

(CBIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

11/22/2021 | 08:01am EST

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29-December 2, 2021.

The fireside chat will be available on-demand for registered attendees via the Piper Sandler conference site beginning Monday, November 22, 2021 at 10:00 am ET until the end of the conference on Thursday, December 2, 2021. To access the fireside chat, please click here. An archived webcast will be available for 90 days on the Events and Presentations section of the Company’s website.

About Catalyst Biosciences, the Protease Medicines company
Catalyst is a research and clinical development biopharmaceutical company focused on developing protease therapeutics to address unmet medical needs in disorders of the complement system. Proteases are natural regulators of this biological system. We engineer proteases to create improved or novel molecules to treat diseases that result from dysregulation of the complement cascade. Our complement pipeline consists of a preclinical C3-degrader program licensed to Biogen for dry age-related macular degeneration (dAMD), an improved Complement Factor I protease CB 4332 for SQ replacement therapy in patients with Complement Factor I (CFI) deficiency and proteases from our ProTUNE™ C3b/C4b degrader and ImmunoTUNE™ C3a/C5a degrader platforms designed to target specific disorders of the complement or inflammatory pathways.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include, without limitation, those regarding swiftly moving forward with clinical development of CB 4332, the continued generation of candidates from the protease platform that will either be licensed or self-developed, reduction of burn rate, the potential that complement will open opportunities in multiple disease settings, submitting an IND for CB 4332, announcing a development candidate from our ProTUNE™ platform that leverages our knowledge of CFI, and successfully completing the transfer of CBIO supported activities to Biogen for CB 2782-PEG, as well as statements about the benefits of our protease engineering platform. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that clinical trials and preclinical studies may be delayed as a result of COVID-19, competitive products, and other factors, that Biogen could terminate our agreement for the development of CB 2782-PEG, that the Company's complement degraders are not yet in human clinical trials and will require additional manufacturing validation and preclinical testing before entering human clinical trials, that the Company may need to raise additional capital, and other risks described in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 4, 2021, the Quarterly Report on Form 10-Q filed with the SEC on November 12, 2021, and in other filings filed from time to time with the SEC. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

Contact:

Ana Kapor
Catalyst Biosciences, Inc.
investors@catbio.com


Primary Logo

Source: Catalyst Biosciences, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about CATALYST BIOSCIENCES, INC.
01/12CATALYST BIOSCIENCES : Investor presentation 5.9 MB
PU
01/12CATALYST BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
AQ
2021Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Con..
AQ
2021CATALYST BIOSCIENCES : Investor presentation 4.7 MB
PU
2021Catalyst Biosciences Announces Change in Corporate Strategy
AQ
2021Catalyst Biosciences to Seek Buyer for its Hemophilia Assets
CI
2021Piper Sandler Adjusts Price Target on Catalyst Biosciences to $4 From $16, Reiterates O..
MT
2021NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
2021JonesTrading Downgrades Catalyst Biosciences to Hold From Buy
MT
2021Raymond James Downgrades Catalyst Biosciences to Market Perform From Outperform
MT
More news
Analyst Recommendations on CATALYST BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 5,15 M - -
Net income 2021 -89,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,22x
Yield 2021 -
Capitalization 20,1 M 20,1 M -
Capi. / Sales 2021 3,90x
Capi. / Sales 2022 2,68x
Nbr of Employees 56
Free-Float 94,3%
Chart CATALYST BIOSCIENCES, INC.
Duration : Period :
Catalyst Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALYST BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,64 $
Average target price 11,00 $
Spread / Average Target 1 619%
EPS Revisions
Managers and Directors
Nassim Usman President, Chief Executive Officer & Director
Seline E. Miller Chief Financial & Accounting Officer
Augustine J. Lawlor Chairman
Andrew Hetherington Senior Vice President-Technical Operations
Grant Blouse Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CATALYST BIOSCIENCES, INC.-29.98%20
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-1.60%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624